Canadian Pacific Kansas City Limited Common Shares vs Regeneron Pharmaceuticals Inc — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $84.17 (market cap $73.98B), while Regeneron Pharmaceuticals Inc trades at $745.44 (market cap $76.14B). The key difference: Canadian Pacific Kansas City Limited Common Shares and Regeneron Pharmaceuticals Inc are close in size by market cap, and Canadian Pacific Kansas City Limited Common Shares pays the higher dividend (0.9%). Which is the better fit depends on your goals.
| CP | REGN | |
|---|---|---|
Market Cap | $73.98B | $76.14B |
Volume | 1,669,828 | 500,239 |
Sector | Industrials | Health |
52-Week High | $96.69 | $852.03 |
52-Week Low | $68.88 | $557.73 |
Enterprise Value | $91.36B | $70.85B |
Dividend Yield | 0.9% | 0.51% |
Typical Hold Time | — | 107 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →